Kite Pharma Inc. (KITE) 66.41 $KITE How Alan Leong Of

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Kite Pharma Inc. (KITE) 66.41 $KITE

How Alan Leong Of BioWatch News Keeps Successful Biotech Investing Simple
Life Sciences Report - Seeking Alpha - Thu Mar 05, 4:53PM CST
Biotechnology can be daunting to comprehend, but understanding is critical to successful investment. BioWatch News Founder Alan Leong has a nose for growth names, and his goal is to make their technology platforms clear to investors who might not...
CTRV: 4.61 (-0.19), GLMD: 9.29 (-0.33), PTBI: 3.50 (-0.05), CNAT: 6.05 (-0.54), GALT: 3.71 (+0.02), SRNE: 13.63 (+0.03), CELG: 118.03 (-2.68), GILD: 101.81 (-1.61), KITE: 66.41 (+1.44), CFRX: 4.61 (+0.28), ICPT: 266.14 (+4.96), JUNO: 52.84 (+0.81), CORT: 3.42 (-0.19)

Is a Surprise Coming for Kite Pharma (KITE) This Earnings Season? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 05, 7:55AM CST
Kite Pharma is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat
KITE: 66.41 (+1.44)

AbbVie's high-priced takeout of Pharmacyclics bodes well for other biotechs with high potential drugs
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 7:52AM CST

VRTX: 126.34 (-0.62), PCYC: 254.56 (+0.34), BMRN: 113.77 (+0.27), UTHR: 160.65 (-0.71), AMGN: 154.88 (-4.72), DYAX: 15.64 (-0.05), JNJ: 100.11 (-2.41), ESPR: 65.28 (+2.12), KITE: 66.41 (+1.44), RCPT: 140.09 (-1.10), PTCT: 71.13 (-1.59), ICPT: 266.14 (+4.96), ABBV: 55.64 (-1.22), JUNO: 52.84 (+0.81), SNY: 47.42 (-0.94)

Kite Pharma Expands Its Research and Development Collaboration With the National Cancer Institute to Develop a Next Generation of Cancer Immunotherapy Products for Solid Tumors
GlobeNewswire - Mon Mar 02, 7:00AM CST
-Focus on T Cell Response to Tumor-Specific Mutations-
KITE: 66.41 (+1.44)

Wall Street's Current Play: 'Immunotherapy Of Cancer'
Chris Lacoursiere - at Seeking Alpha - Thu Feb 26, 10:39AM CST

KITE: 66.41 (+1.44), PPHM: 1.63 (+0.06), JUNO: 52.84 (+0.81)

Billionaire George Soros Just Bought These 3 Stocks: Should You?
George Budwell, The Motley Fool - Motley Fool - Sat Feb 21, 11:07AM CST
Billionaire superinvestor George Soros is among the most closely watched figures in the investing world because he's been stunningly successful at consistently picking winners, and perhaps more importantly, avoiding big losers for a long period of...
AGN: 233.51 (-1.90), ACT: 289.92 (-5.78), KITE: 66.41 (+1.44), AMGN: 154.88 (-4.72)

Immuno-Oncology Promises Continued Wealth And Health: LifeTech Capital's Stephen Dunn
Life Sciences Report - Seeking Alpha - Fri Feb 20, 11:11AM CST
Immuno-oncology-disabling cancer's defenses so that a patient's own immune system can seek it out and destroy it-took center stage in the drug development world in 2014. Stephen Dunn of LifeTech Capital believes that preeminence will continue in...
BLCM: 24.48 (+0.13), KITE: 66.41 (+1.44), PFE: 33.97 (-0.50), MRK: 56.84 (-1.14), JUNO: 52.84 (+0.81), BMY: 65.12 (-0.93), CBMG: 33.99 (+1.60), NVS: 97.46 (-1.49)

Kite Pharma Establishes Manufacturing Capabilities to Support Development and Commercialization of CAR and TCR Cancer Immunotherapy Products
GlobeNewswire - Thu Feb 19, 7:07AM CST
Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that it has entered into a lease agreement for a commercial manufacturing facility in El Segundo, California, which is adjacent to Los Angeles International Airport. Kite also recently secured a lease for a clinical manufacturing facility in Santa Monica, California. The two facilities will not only support the planned clinical trials of Kite's product candidates, but also will prepare Kite for the commercial launch and supply of its lead product candidate, KTE-C19, anticipated in 2017.
KITE: 66.41 (+1.44)

IPO Stock Watch: Health Care IPO Market Losing Grip
at Investor's Business Daily - Tue Feb 17, 1:21PM CST
The health care IPO market, after a blazing 2014, is showing signs of illness. Three small IPOs planned for this week, all hailing from the health care sector, are trying once again after previously postponing their offerings. They plan to raise a...
KITE: 66.41 (+1.44), ONCE: 58.01 (+0.48), INOV: 30.53 (-0.11), NVTA: 18.70 (+0.43), BLPH: 11.64 (-0.01)

Track What Biological Products Companies Are Up To: Special Research on Gilead, Halozyme, Heska, Idera, and Kite Pharma
PR Newswire - Tue Feb 17, 7:50AM CST
Editor Note: For more information about this release, please scroll to bottom.
HALO: 15.20 (-0.19), IDRA: 4.68 (-0.21), HSKA: 25.05 (+2.20), KITE: 66.41 (+1.44), GILD: 101.81 (-1.61)

Be Careful: These Biotechs Have Run Too Far Too Fast
Motley Fool Staff - Motley Fool - Mon Feb 16, 10:13AM CST
In biotechnology, stocks sometimes get a bit too far in front of themselves. When that happens, shares can take a big dip; so we asked three Motley Fool experts to weigh in on which stocks they think have climbed too much, too quickly. : On the...
JNJ: 100.11 (-2.41), PCYC: 254.56 (+0.34), JPM: 60.89 (-1.11), GILD: 101.81 (-1.61), KITE: 66.41 (+1.44), ABBV: 55.64 (-1.22), JUNO: 52.84 (+0.81), NVS: 97.46 (-1.49), CELG: 118.03 (-2.68)

Amgen's Skin Cancer Drug to Face FDA Advisory Panel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 3:10PM CST
Amgen's (AMGN) experimental skin cancer treatment, talimogene laherparepvec, is scheduled to face twin FDA advisory committees on Apr 29, 2015.
BMRN: 113.77 (+0.27), KITE: 66.41 (+1.44), MRK: 56.84 (-1.14), AMGN: 154.88 (-4.72)

NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST

OCAT: 6.63 (+0.01), VCEL: 3.65 (-0.02), PSTI: 3.10 (-0.11), NBS: 3.79 (-0.18), GSK: 46.73 (-0.87), IMUC: 0.59 (-0.01), KITE: 66.41 (+1.44), BAX: 67.73 (-1.48), ONCE: 58.01 (+0.48), JUNO: 52.84 (+0.81), ATHX: 2.98 (+0.10), CUR: 3.79 (+0.02)

Will Kite Pharma (KITE) Disappoint this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 9:40AM CST
Kite Pharma, Inc. (KITE) is expected to report fourth-quarter 2014 results on Feb 13.
ACT: 289.92 (-5.78), KITE: 66.41 (+1.44), AMGN: 154.88 (-4.72), ACOR: 34.74 (-0.56)

Not For The Faint Of CAR-T: The CAR-T Landscape In Early 2015
EP Vantage - Seeking Alpha - Fri Feb 06, 1:26PM CST
This is an extract from a longer report. If you followed last year's explosion of enthusiasm in CAR therapies you might have assumed that this was a super-novel approach that had just burst onto the scientific stage. In fact work on the synthetic...
BLUE: 113.14 (+0.91), CLRB: 2.59 (+0.08), BLCM: 24.48 (+0.13), KITE: 66.41 (+1.44), JUNO: 52.84 (+0.81), NVS: 97.46 (-1.49)

Northwest Has A Differentiated Technology Platform In The Emerging Immuno-Oncology Landscape
Smith On Stocks - Seeking Alpha - Fri Feb 06, 11:08AM CST
Investment Overview Linda Powers was invited to the 7th Annual Phacilitate Immunotherapy Forum in Washington D.C. to speak on the potential role of personalized immunotherapy drugs in the treatment of cancer. She was prominently featured in the ...
NWBO: 7.50 (+0.14), KITE: 66.41 (+1.44), JUNO: 52.84 (+0.81)

14 IPOs You Wish You Bought in 2014 (And Made a Killing On)
at The Street - Thu Feb 05, 7:36AM CST
Getting in on a hot IPO may prove difficult for most retail investors. That doesn't mean there aren't gains to be made. Here are the best performing IPOs in 2014.
ZFGN: 38.75 (-0.45), GPRO: 40.13 (-0.95), CLDN: 24.00 (+2.54), ZEN: 23.01 (-0.42), ASPX: 69.14 (-0.32), TNET: 33.06 (-0.45), NVRO: 42.10 (-0.92), OCUL: 39.60 (-0.16), RDUS: 47.47 (+1.29), ALDR: 26.50 (+0.81), IRMD: 13.95 (-0.01), KITE: 66.41 (+1.44), TUBE: 12.73 (+0.09), VBLT: 3.75 (-0.02)

KITE Pharma - A Standout IPO In 2014 With Even Better Returns To Come In 2015
Financial Markets Wizard - Seeking Alpha - Wed Feb 04, 12:24PM CST
2014 was a record-breaking year for initial public offerings (IPOs). Businesses as wide ranging as furniture retailers, fast food outlets and digital technology firms began trading on the stock market. This proved to be a feast for the writers of...
KITE: 66.41 (+1.44)

Kite Pharma Expands and Strengthens Leadership Team
PR Newswire - Tue Feb 03, 3:30PM CST
Kite Pharma, Inc., (Nasdaq: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced the appointments of Salah D. Kivlighn, Ph.D., as Vice President, Marketing, and Anthony J. Polverino, Ph.D., as Vice President, Research. Dr. Kivlighn will play a critical role spearheading the Company's marketing strategy. He will report to Cynthia M. Butitta, Chief Financial Officer and Chief Operating Officer. Dr. Polverino will lead the research and development of various eACT(TM) candidates. He will report to Margo R. Roberts, Ph.D., Chief Scientific Officer.
KITE: 66.41 (+1.44)

Kite Pharma to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 3:30PM CST
Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that Arie Belldegrun, M.D., FACS, Kite's President and Chief Executive Officer, will present a corporate overview at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015 at 1:30 p.m. Eastern Time at the Waldorf Astoria in New York City. Dr. Belldegrun will also take part in the panel Personalizing Oncology Treatments at 8:00 a.m. Eastern Time, on the same day.
KITE: 66.41 (+1.44)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

BETR's Legal Tangle: A Deeper Dive into Investor Turmoil

Updated Category News Views 139

BETR's Shaky Ground: When Promises Fall Short In the rough-and-tumble world of finance, there's little room for empty promises. Better Home & Finance Holding Company (NASDAQ: BETR) might have to learn that the hard way. Investors who snagged shares between March 13 and August 6, 2026, are now clutching their heads as they watch their investments nosedive. When companies...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 83

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
Cargo Drones to Skyrocket with $9.14B Value by 2031

Updated Category News Views 141

Riding the Drone Wave I tell you what, folks, the whole business of cargo drones is getting frickin' interesting. These flying gizmos, once dismissed as science fiction, are now barging their way into logistics discussions like an uninvited guest who's too worthwhile to ignore. MarketsandMarkets™ reckons this market's about to smash through the $9 billion ceiling by...

Continue Reading
Medtronic's Bold Move to Own Carotid Market Full-Scale

Updated Category News Views 163

When a giant like Medtronic makes a move, you can bet investors take notice, and this latest acquisition is no exception. They’re reaching into their deep pockets to acquire Contego Medical, a company shaking up the world of carotid artery disease treatments. It’s a tactical strike to solidify their leadership in cardiovascular solutions. Medtronic's Bet on Innovation...

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 88

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
Rock & Roll Hall of Fame's 2026 Induction Triumph

Updated Category News Views 158

A Night of Unstoppable Talent The Rock & Roll Hall of Fame's 2026 Induction Ceremony and boy, what a spectacle it was. Held on a lively Saturday night, November 14, in Los Angeles, it wasn't just an event; it was an electrifying testament to music's profound impact. With the grand ceremony kicking off at the historic city of stars, this year's induction turned the dial to...

Continue Reading
Laboratory Filtration Market Expands to $6.55B by 2031

Updated Category News Views 68

A Niche Ready to Explode The laboratory filtration market isn't exactly the sort of thing that grabs headlines in the business section, but its growth is worth giving a second look. By 2031, this market's expected to hit $6.55 billion—up from $4.49 billion in 2026. If you think that's not impressive, chew on a 7.9% CAGR for the next few years. That's like watching your...

Continue Reading
Engrain's Geospatial Innovation Pushes Property Mapping Forward

Updated Category News Views 125

Pushing the Boundaries of Property Mapping How far can you expand the boundaries of property mapping tech? Well, Engrain seems hell-bent on finding out by cranking their innovations up a notch. The Denver-based stalwart in interactive mapping is rolling out some mind-boggling enhancements that could redefine how the multifamily housing sector operates. This isn't just...

Continue Reading
SKE Capitalizes on Halloween Events in London

Updated Category News Views 88

SKE's Bold Step into London's Halloween Vibe Hah! Who would've thought that vaping and Halloween could be a match made in heaven? This year, SKE threw its hat into the ring and wrestled for attention in London’s bustling Halloween music scene. Imagine an entire warehouse pulsing not just with beat-heavy electronic music, but the energy of vaping enthusiasts courtesy of...

Continue Reading
Ainstein Expands Kansas Operations Amid Sensor Demand Surge

Updated Category News Views 91

Ainstein's Expansion Conquers New Heights in Radar Tech Ainstein just cranked open a whole new chapter right in the heart of Kansas. And believe me, it's not your average ribbon-cutting story. This shiny new facility in Lenexa is locked and loaded to roll out 44,000 radar sensors a year. It's part of a no-nonsense plan to keep up with soaring demand for their tech across...

Continue Reading

Top 5 Most Recently Viewed Articles

Consumers Warned About Allergy Risk in Cheesecake Recall

Updated Category News Views 412

Important Allergy Notification Regarding Dessert Holdings' Cheesecake Dessert Holdings LLC has recently made an urgent recall for their Target brand Favorite Day™ Gourmet New York Style Cheesecake, packaged in 6oz/2ct servings. The recall applies to items under Lot code 25028A1 000039133. This action is due to a labeling error that resulted in undeclared pecans present...

Continue Reading
Top Tech Stocks to Consider for Your Portfolio This Quarter

Updated Category News Views 165

Why Tech Stocks Might Be Your Best Bet In today's market, investors are continuously on the lookout for tech stocks that are currently undervalued but hold the promise of recovery. These stocks might be oversold, presenting a golden opportunity for those aiming to strengthen their portfolios. This article focuses on notable players within the technology sector who have...

Continue Reading
Analyzing Tesla and Constellation Brands' Market Prospects

Updated Category News Views 301

Current Market Trends and Overview This week, market attention is drawn to various economic indicators, including job reports and speeches from influential figures. As concerns about inflation and corporate earnings persist, investors are weighing their options carefully. The overall sentiment in the stock market has improved recently, with major indices achieving new...

Continue Reading
Current Trends in Cryptocurrency Markets: BTC, DOGE, ETH Updates

Updated Category News Views 372

Bitcoin Sees Resistance Below $90,000 In recent trading sessions, Bitcoin has remained just under the pivotal $90,000 threshold. This situation has arisen due to factors like cooling inflation data, which has cultivated a cautious attitude among investors. The current market scenario has sparked discussions about potential future movements for Bitcoin and its rivals....

Continue Reading
Jura Energy Files 2024 Financials and Reserves Report Overview

Updated Category News Views 284

Updates from Jura Energy Corporation’s Recent Filing Jura Energy Corporation (TSX-V: JEC), based in Calgary, Alberta, has recently announced an important update regarding its financial and operational status. The company has filed its consolidated annual audited financial statements for the years ending 2024 and 2023. This filing also includes the management’s...

Continue Reading